|
||
| |||||||
|
Introduction: The pharmaceutical dynamic for melanoma is changing. Vaccine therapy has evolved and clinical benefits are emerging: melanoma now offers potential benefits through orphan drug designation and a level playing field for novel agents. This In-Depth Analysis discusses for increased pharmaceutical intervention in the context of cost-effective drug development and marketing for malignant melanoma. Scope: * Epidemiological summary of malignant melanoma, by stage, in the seven major pharmaceutical markets plus Australia, 2002-2010 * Country-by-country review of surgical, immunotherapy and chemotherapy practice patterns for melanoma, by stage * Overview of current and pipeline drug and immunological therapies for melanoma, with clinical data and SWOT analyses * Forecast for key drugs used to treat melanoma, 2002-2010, with discussion Report Highlights: The immunotherapies market will feature the greatest changes, with established agents being augmented by the introduction of vaccine therapies. Improvements in reporting and staging of incident cases in other markets are likely to identify larger drug-treated populations, but the increases are not likely to affect the size of the melanoma pharmaceutical market. Reasons to Purchase: * Find out why the melanoma market holds high growth potential * Enhance your understanding of country-specific treatment patterns and identify areas of opportunity * Understand why novel agents have a high degree of sales potential for melanoma Publisher: Datamonitor Oncology Reports To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a272
|
|
|
